STTK vs. SLRN, IGMS, TBPH, ANL, FULC, TVTX, TRDA, APLT, KALV, and CDMO
Should you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Acelyrin (SLRN), IGM Biosciences (IGMS), Theravance Biopharma (TBPH), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), Travere Therapeutics (TVTX), Entrada Therapeutics (TRDA), Applied Therapeutics (APLT), KalVista Pharmaceuticals (KALV), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical preparations" industry.
Shattuck Labs (NASDAQ:STTK) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.
Acelyrin has a net margin of 0.00% compared to Shattuck Labs' net margin of -5,268.44%. Acelyrin's return on equity of -50.56% beat Shattuck Labs' return on equity.
In the previous week, Shattuck Labs had 2 more articles in the media than Acelyrin. MarketBeat recorded 2 mentions for Shattuck Labs and 0 mentions for Acelyrin. Acelyrin's average media sentiment score of 0.55 beat Shattuck Labs' score of 0.00 indicating that Acelyrin is being referred to more favorably in the news media.
58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 9.9% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Shattuck Labs has higher revenue and earnings than Acelyrin. Shattuck Labs is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Shattuck Labs currently has a consensus price target of $20.00, suggesting a potential upside of 88.86%. Acelyrin has a consensus price target of $23.67, suggesting a potential upside of 458.18%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Shattuck Labs.
Shattuck Labs received 16 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 73.53% of users gave Shattuck Labs an outperform vote while only 56.25% of users gave Acelyrin an outperform vote.
Summary
Shattuck Labs and Acelyrin tied by winning 8 of the 16 factors compared between the two stocks.
Get Shattuck Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shattuck Labs Competitors List
Related Companies and Tools
